Literature DB >> 35659262

Catheter-related bloodstream Mycobacterium wolinskyi infection in an umbilical cord blood transplant recipient: a case report.

Emiri Muranaka1,2, Ryota Hase3,4, Yoshikazu Utsu5, Tomohisa Watari6, Yoshihito Otsuka6, Naoto Hosokawa4.   

Abstract

BACKGROUND: Catheter-related bloodstream infection (CRBSI), caused by rapidly growing mycobacteria (RGM), is a rare infectious complication in hematopoietic stem cell transplant (HSCT) recipients and can often be misdiagnosed as Gram-positive rod (GPR) bacteremia. CASE
PRESENTATION: We present a case of CRBSI caused by Mycobacterium wolinskyi, a rare RGM, in a 44-year-old female patient who received an umbilical cord blood transplant.
CONCLUSIONS: Rapidly growing mycobacteria can stain as GPRs and may grow in routine blood culture media after 3-4 days of incubation. These features are not widely known to clinicians, and acid-fast staining is therefore recommended when unidentifiable GPRs are detected in blood cultures, especially in immunocompromised patients, such as those with hematologic malignancies or intravascular devices.
© 2022. The Author(s).

Entities:  

Keywords:  Case report; Mycobacterium wolinskyi; Rapidly growing mycobacteria; Umbilical cord blood transplant; Unidentifiable Gram-positive rods

Mesh:

Year:  2022        PMID: 35659262      PMCID: PMC9167550          DOI: 10.1186/s12879-022-07495-z

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.667


Background

Mycobacterium wolinskyi is a rapidly growing non-tuberculous mycobacteria (NTM) that belongs to the Mycobacterium smegmatis group [1]. Infections caused by M. wolinskyi are rare, with less than 30 cases reported to date. Most of them are skin and soft-tissue infections or prosthetic joint infections after trauma or surgery, and only four were bloodstream infections [2-5]. In hematopoietic stem cell transplant (HSCT) recipients, catheter-related bloodstream infections (CRBSI) are the most commonly encountered NTM infectious complications [6, 7], mostly caused by rapidly growing mycobacteria (RGM) [7], which are defined as mycobacteria growing within 7 days [8]. They may grow in routine blood culture media after 3–4 days of incubation [8, 9]. However, the diagnosis is often difficult and delayed, since RGM may be misidentified as Gram-positive rods (GPRs) rather than acid-fast bacilli [10-14]. Here, we have described a case of peripherally inserted central catheter-associated bloodstream infection due to M. wolinskyi, diagnosed by acid-fast staining in a second umbilical cord blood transplant recipient. We have also reviewed the clinical course and outcomes of previously reported M. wolinskyi bacteremia.

Case presentation

A 44-year-old woman had undergone first allogeneic cord blood transplantation (CBT, 2.35 × 106/kg nucleated cells, two locus mismatch) for acute myeloid leukemia after two courses of induction therapy that led to hematologic complete remission. The patient was pre-treated with cytarabine, cyclophosphamide, and total body irradiation conditioning. Graft-versus-host disease prophylaxis consisted of cyclosporine and methotrexate. Her medical, family, and social histories were unremarkable. The patient underwent a second CBT (2.0 × 107/kg nucleated cells) 32 days after the first due to graft failure. Seven days after the second CBT, she presented with high fever and shaking chills. Upon physical examination, painful induration with linear erythema along the superficial veins was observed in the peripherally inserted central catheter (PICC) site, which was inserted on the day after the second CBT. Two sets of blood samples were drawn for culture and meropenem treatment was started. The blood culture was positive on the third day of incubation (10 days after the second CBT). Gram staining of a positive blood culture revealed GPR (Fig. 1, left), and vancomycin was added thereafter. Fever persisted and PICC was removed on day 11 after the second CBT (PICC was maintained for 10 days). The VITEK® 2 system (bioMérieux, Durham, NC, USA) was not able to identify the organism. Blood cultures drawn on days 10, 11, 15, and 22 after CBT were also positive for GPR. On the 14th day after the second CBT, Ziehl–Neelsen staining was performed and was found to be positive for acid-fast bacilli (Fig. 1, right).
Fig. 1

Left Gram staining of blood cultures shows diphtheroid bacilli and short branching filaments. Right Ziehl–Neelsen staining of colonies obtained by subculture

Left Gram staining of blood cultures shows diphtheroid bacilli and short branching filaments. Right Ziehl–Neelsen staining of colonies obtained by subculture The nucleotide sequences were analyzed using the National Center for Biotechnology Information BLAST (http://blast.ncbi.nlm.nih.gov). The almost full-length (1442-bp) 16S rDNA gene sequence of the isolate shared 100% similarity to M. wolinskyi type strain ATCC 700010. In addition to PICC removal, imipenem/cilastatin (IPM/CS), amikacin (AMK), levofloxacin (LVX), and azithromycin (AZM) were started empirically. Antibiotic susceptibilities were determined using the broth microdilution method (BrothMIC RGM®; Kyokuto, Tokyo, Japan) based on the Clinical and Laboratory Standards Institute M24 recommendations (Table 1) [15].
Table 1

Results of antimicrobial susceptibility testing of Mycobacterium wolinskyi isolated in our case

AntibioticMIC (mg/mL)S ≤ IR > 
Amikacin ≤ 4163264
Tobramycin > 1648–1632
Imipenem1648–1632
Levofloxacin2248
Moxifloxacin1124
Clarithromycin64248
Trimethoprim–sulfamethoxazole152/838/2No76/4
Doxycycline ≤ 0.512–816
Linezolid281632

MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant

Results of antimicrobial susceptibility testing of Mycobacterium wolinskyi isolated in our case MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant According to the susceptibilities, IPM/CS and AZM were discontinued, and minocycline (MIN) was added. LVX was changed to moxifloxacin (MFX) based on previous case series [4]. After 1 month of intravenous administration of AMK, the patient was discharged on an oral regimen of MFX and MIN. Although MXF had to be discontinued after 4 months due to nausea, MIN was continued for 6 months. After 3 weeks of combination antimicrobial therapy, blood cultures became negative. She showed successful engraftment by day 28. The patient responded well to therapy and no recurrence of infection was identified at 1-year follow-up.

Discussion and conclusion

Herein, we have described a case of PICC-related bloodstream M. wolinskyi infection in an umbilical cord blood transplant recipient. The findings suggested that acid-fast staining should be conducted when unidentifiable GPRs are detected in blood cultures, especially in immunocompromised patients with long-term indwelling catheters. Misidentification of RGM as GPRs, including Corynebacterium spp. [11, 14, 16, 17], Rhodococcus, Brevibacterium [10], Actinomyces, or Nocardia [17, 18], had been reported earlier and performing acid-fast staining is recommended for cases in which Gram-positive bacilli have been cultured from high-risk patients. One study at a quality-control center in Switzerland [13], in which investigators delivered M. fortuitum specimens labelled as ‘pus from an abscess’ to 50 laboratory facilities, had shown only 13 of 50 (26%) to be correctly identified as “RGM” or “M. fortuitum”; 46% were incorrectly identified as Nocardia sp., 8% as Rhodococcus sp. Gram-positive rods, Actinomyces, Streptococcus, or Corynebacterium. Notably, all laboratories that did not use acid-fast stains were unable to correctly identify the organisms. We reviewed all available literature for the five cases of M. wolinskyi bloodstream infections, including the present one (Table 2). Three of the five cases had hematologic malignancies as comorbidities. In all three cases for which Gram stain results were available, blood cultures showed GPRs. An intravascular device was present in 4 of the 5 cases, and the device was removed in 3 cases. Blood cultures were positive within 2 to 5 days of incubation for all cases. The prognosis was generally good, especially for those whose devices had been removed. No death was reported during the treatment.
Table 2

Summary of published cases of M. wolinskyi bacteremia

AgeGenderComorbiditiesType of infectionTreatmentIntravascular devicesDevice removalGram stainOutcomeTime to positive blood culture (days)
Chen et al. [2]22fNHL on chemotherapyBSI/septic arthritis in native jointSurgical debridement + AMK (1 month), MXF and MIN (6 months)Venous portYesN/AN/A3
Ohno et al. [3]55fCML on chemotherapy

BSI

No source identified

AMK (1 month), MIN and LVX (6 months)NoneN/AGPRGood outcome at 1.5-year follow-up5
Ariza-Heredia et al. [4]16mCongenital aortic stenosis status post-Ross procedureBSI, likely endocarditis and infected aortic root graftAMK, MXF and DOXY (ongoing)Vascular graftYesN/AUnderwent pulmonary artery conduit replacement5
Kitajima et al. [5]82mStatus-post AVR and MVRProsthetic valve endocarditisAMK, IPM and CLR (6 weeks) then CIP and MIN (total 12 months)Prosthetic valveNoGPRCure5
Present case43fAML post hematopoietic stem cell transplantationCatheter related blood stream infection

AMK, IPM/CS, LVX and AZM (6 days)

AMK, IPM/CS, LVX and MIN (13 days), AMK, MXF and MIN (15 days)

then MXF (4 months) and MIN (6 months)

PICCYesGPRCure2

NHL non-Hodgkin lymphoma, CML chronic myeloid leukemia, AVR aortic valve replacement, MVR mitral valve replacement, AML acute myeloid leukemia, BSI bloodstream infection, AMK amikacin, MXF moxifloxacin, MIN minocycline, LVX levofloxacin, IPM imipenem, CLR clarithromycin, CIP ciprofloxacin, AZM azithromycin, PICC peripherally inserted central catheter, IPM/CS imipenem/cilastatin, N/A not available, GPR Gram-positive rod

Summary of published cases of M. wolinskyi bacteremia BSI No source identified AMK, IPM/CS, LVX and AZM (6 days) AMK, IPM/CS, LVX and MIN (13 days), AMK, MXF and MIN (15 days) then MXF (4 months) and MIN (6 months) NHL non-Hodgkin lymphoma, CML chronic myeloid leukemia, AVR aortic valve replacement, MVR mitral valve replacement, AML acute myeloid leukemia, BSI bloodstream infection, AMK amikacin, MXF moxifloxacin, MIN minocycline, LVX levofloxacin, IPM imipenem, CLR clarithromycin, CIP ciprofloxacin, AZM azithromycin, PICC peripherally inserted central catheter, IPM/CS imipenem/cilastatin, N/A not available, GPR Gram-positive rod We reported a case of peripherally inserted central catheter-associated bloodstream infection caused by Mycobacterium wolinskyi in a second umbilical cord blood transplant recipient. M. wolinskyi is an RGM and a rare cause of bacteremia in immunosuppressed patients with hematologic malignancies or intravascular devices. Rapidly growing mycobacteria may grow in routine blood culture media and sometimes be confused with Gram-positive rods, resulting in delayed diagnosis. In immunocompromised patients or those with intravascular devices and bacteremia caused by “unidentifiable Gram-positive rods”, acid-fast staining should be performed.
  16 in total

1.  Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial Taxonomy.

Authors:  B A Brown; B Springer; V A Steingrube; R W Wilson; G E Pfyffer; M J Garcia; M C Menendez; B Rodriguez-Salgado; K C Jost; S H Chiu; G O Onyi; E C Böttger; R J Wallace
Journal:  Int J Syst Bacteriol       Date:  1999-10

2.  Mycobacterium mucogenicum from the Hickman line of an immunocompromised patient.

Authors:  C Marshall; J Samuel; A Galloway; S Pedler
Journal:  J Clin Pathol       Date:  2007-08-03       Impact factor: 3.411

3.  Misidentification of Mycobacterium peregrinum, the causal organism of a case of bacteremia and automatic implantable cardioverter defibrillator-associated infection, due to its unusual acid-fast staining characteristics.

Authors:  William R Short; Christopher Emery; Mallika Bhandary; Judith A O'Donnell
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 4.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 5.  Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species.

Authors:  G L Rodgers; J E Mortensen; D Blecker-Shelly; M C Fisher; S S Long
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

Review 6.  Mycobacterium wolinskyi: a case series and review of the literature.

Authors:  Ella J Ariza-Heredia; Ala S Dababneh; Mark P Wilhelm; Nancy L Wengenack; Raymund R Razonable; John W Wilson
Journal:  Diagn Microbiol Infect Dis       Date:  2011-09-25       Impact factor: 2.803

7.  Native-valve endocarditis caused by Mycobacterium chelonae, misidentified as polymicrobial gram-positive bacillus infection.

Authors:  Daisuke Takekoshi; Omar Al-Heeti; Patrick Belvitch; Dean E Schraufnagel
Journal:  J Infect Chemother       Date:  2012-10-10       Impact factor: 2.211

8.  Fatal Mycobacterium abscessus endocarditis misidentified as Corynebacterium spp.

Authors:  John C Williamson; Todd A Miano; Michael R Morgan; Elizabeth L Palavecino
Journal:  Scand J Infect Dis       Date:  2010-03

9.  First case report of prosthetic valve endocarditis caused by Mycobacterium wolinskyi.

Authors:  Heita Kitajima; Yuichiro Oba; Takahisa Ohira; Tomohiro Asaoka; Yoshihiro Atsumi; Takahiro Nakajima; Takayuki Okura
Journal:  J Infect Chemother       Date:  2021-01-02       Impact factor: 2.211

10.  Bacteremia caused by Mycobacterium wolinskyi.

Authors:  Yu-Chuan Chen; Ruwen Jou; Wei-Lun Huang; Shao-Tsung Huang; Keng-Chang Liu; Chorng-Jang Lay; Shu-Mei Chang; Chih-En Tseng; Chun-Liang Lai; Yu-Chieh Su
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.